Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3Other hematologic neoplasm 3Tumor-Agnostic 1Other neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 3Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Infusions, Intravenous × Other hematologic neoplasm × Clear all
NCT03850574 2025-08-26

TUSCANY

Aptose Biosciences Inc.

Phase 1/2 Recruiting
240 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05448599 2023-03-15

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2 Unknown
120 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05001451 2022-07-20

Study of GDX012 in Patients With MRD Positive AML

GammaDelta Therapeutics Limited

Phase 1 Terminated
3 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡